Study Summary: This research aims to test how effective and safe a new medicine called KarXT is for adults with schizophrenia. Schizophrenia is a mental disorder that affects how a person thinks, feels, and behaves. This study is for people who are currently taking other antipsychotic medicines but are not seeing enough improvement. KarXT combines two drugs, xanomeline and trospium chloride, taken twice daily.
Key Points:
- Duration: The study lasts for 6 weeks, with several visits to the clinic required.
- Eligibility: Participants must be 18-64 years old, have a schizophrenia diagnosis, and have been on a stable dose of certain antipsychotic medications for at least 8 weeks.
- Compensation & Safety: The study includes monitoring for safety, but there are no details on compensation provided. There are risks involved, such as potential side effects from the study drug.
Participants will be randomly assigned to receive either the KarXT or a placebo (a harmless pill with no medicine). The study will check if KarXT helps reduce schizophrenia symptoms by using a special scale called the PANSS (Positive and Negative Syndrome Scale).
How understandable was the trial content above?
Hard to understand
Easy to understand